Intravenous immunoglobulins for neonatal alloimmune neutropenia refractory to recombinant human granulocyte colony-stimulating factor

Am J Perinatol. 2011 Jun;28(6):461-6. doi: 10.1055/s-0030-1270113. Epub 2010 Dec 6.

Abstract

Neonatal alloimmune neutropenia (NAN) results from neutrophil destruction by transplacental maternal neutrophil-specific immunoglobulin G (IgG) antibodies directed against the antigen inherited from the father. Treatment is usually based on recombinant human granulocyte colony-stimulating factor (G-CSF) and prevention or treatment of infection. We report the case of neutropenia in a newborn discovered because of fetomaternal infection. The bone marrow biopsy showed normal cellularity. Granulocyte typing, granulocyte cross-matching, and serum assays showed anti-neutrophil antibodies specific for human neutrophil antigen-1c, an antigen rarely involved in this disease. This NAN was refractory to G-CSF but responded to intravenous immunoglobulin (IVIG). IVIG should be considered as a second-line treatment in NAN refractory to G-CSF. Clinical trials, however, are required to define the optimal management of NAN, a rare but probably underestimated life-threatening situation for newborns.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Escherichia coli Infections / complications*
  • Female
  • Granulocyte Colony-Stimulating Factor / therapeutic use
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Infant, Newborn
  • Isoantigens / blood
  • Male
  • Neutropenia / drug therapy*
  • Neutropenia / immunology
  • Neutropenia / microbiology
  • Neutrophils / immunology*
  • Recombinant Proteins

Substances

  • Immunoglobulins, Intravenous
  • Isoantigens
  • Recombinant Proteins
  • neutrophil-specific antigen SH
  • Granulocyte Colony-Stimulating Factor